Collaborations & Alliances
Related Searches:
Filter by:
February 29, 2008
Wyeth Pharmaceuticals has ended its collaboration agreements with Solvay Pharmaceuticals for the development and commercialization of bifeprunox, an investigational atypical antipsychotic drug, as well as other compounds in earlier stages of developm…
Read More »
February 19, 2008
Memory Pharmaceuticals Corp. plans to conduct a clinical study of MEM 3454, the company's lead nicotinic alpha-7 partial agonist, in patients with schizophrenia based on two biomarkers, P50 sensory gating and mismatch negativity. Development partner,…
Read More »
February 5, 2008
Amgen and Takeda Pharmaceutical Co. Ltd. entered an agreement under which Takeda will develop and commercialize as many as 13 molecules from Amgen’s pipeline for the Japanese market. The collaboration includes early to mid-clinical-stage candid…
Read More »
January 22, 2008
Bristol-Myers Squibb has exercised its option to develop and commercialize Exelixis' compound XL139. Exelixis will receive a $20 million milestone payment and has exercised its option to co-develop and co-commercialize the drug in the U.S. BMS will l…
Read More »
January 18, 2008
Azopharma Product Development Group, Inc. and Accu-Break Pharmaceuticals, Inc. (ABP) have signed a strategic alliance agreement in which Azopharma will develop products based on ABP’s Accu-Break tablet technologies. The agreement spans five yea…
Read More »
January 18, 2008
Helix BioPharma Corp. has signed an agreement with KBI Biopharma, Inc. to develop a process for preparing L-DOS47 in a lyophilized (freeze-dried powder) vial format for clinical testing.
"This new arrangement advances the C…
Read More »
January 10, 2008
Celltrion, Inc. and CSL Ltd., an Australian biopharmaceutical company, have signed an agreement for the development and supply of CSL 360, an experimental monoclonal antibody for the treatment of acute myeloid leukemia (AML). CSL is currently conduct…
Read More »
January 8, 2008
Genzyme Corp. and Isis Pharmaceuticals, Inc. have formed a strategic alliance in which Genzyme will develop and commercialize mipomersen, Isis' lipid-lowering treatment for high-risk cardiovascular patients that uses novel antisense technology. As pa…
Read More »
January 7, 2008
Catalyst Biosciences, Inc. has entered into an exclusive worldwide research and license agreement with Centocor R&D, Inc. Centocor will support Catalyst's discovery research and preclinical development of Alterase drug candidates against two targ…
Read More »
December 20, 2007
Merck Serono and Flamel Technologies have entered into a collaboration to investigate the applicability of Flamel's Medusa technology for the extended release of a therapeutic protein of Merck Serono’s portfolio. Merck Serono will make an upfro…
Read More »
December 20, 2007
MPI Research and Shanghai Medicilon have formed a joint venture in preclinical services. Medicilon-MPI Preclinical Research (Shanghai) LLC will be located initially at the Zhangjiang Hi-Tech Park in Shanghai, China. The group will open a 50,000-sq.-f…
Read More »
December 17, 2007
Lilly and Ambrx Inc. have entered into a collaboration to discover and develop novel treatments in several therapeutic areas, including metabolic diseases, central nervous system disorders and other diseases. The collaboration will apply Ambrx's uniq…
Read More »
December 17, 2007
Amgen and Oxford Genome Sciences (UK) have entered into a strategic collaboration to discover, develop and commercialize novel therapeutic antibodies for the treatment of cancer. This collaboration will enable OGS to strengthen its pipeline of…
Read More »
December 14, 2007
GlaxoSmithKline has exercised its option to exclusively license XL880 from Exelixis for further development and commercialization. XL880 is a small molecule compound currently being evaluated in Phase II trials in patients with papillary renal cell c…
Read More »
December 12, 2007
Merck has filed an IND with the FDA for a cancer vaccine candidate that targets telomerase. Merck is developing the vaccine under a July, 2005 Research, Development and Commercialization License Agreement with Geron Corp., which provided exclusive wo…
Read More »
